The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies

Meng Michelle Xu, Yang Pu, Yuan Zhang, Yang Xin Fu

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Accumulating evidence indicates that the efficacy of tumor-targeted therapies relies on the host immune response, including targeted small-molecule and antibody approaches that were not previously thought to have an immune component. Here, we review the current understanding of how targeted therapies on tumor cells could have a major impact on the immune response, and how this relates to the therapeutic efficacy of these approaches. In this context, we evaluate different strategies that combine targeted therapies with immunotherapy approaches, and discuss past and ongoing clinical trials. We highlight gaps in knowledge, and argue that significant progress for combined therapies will require a better understanding of the complex interactions between immune cells, the tumor, and the tumor microenvironment (TME) in different cancer settings.

Original languageEnglish (US)
Pages (from-to)141-153
Number of pages13
JournalTrends in Immunology
Volume37
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Adaptive Immunity
Neoplasms
Therapeutics
Tumor Microenvironment
Immunotherapy
Clinical Trials
Antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. / Xu, Meng Michelle; Pu, Yang; Zhang, Yuan; Fu, Yang Xin.

In: Trends in Immunology, Vol. 37, No. 2, 01.02.2016, p. 141-153.

Research output: Contribution to journalReview article

Xu, Meng Michelle ; Pu, Yang ; Zhang, Yuan ; Fu, Yang Xin. / The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. In: Trends in Immunology. 2016 ; Vol. 37, No. 2. pp. 141-153.
@article{25c0c826e80947748bbd8a9df6a76320,
title = "The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies",
abstract = "Accumulating evidence indicates that the efficacy of tumor-targeted therapies relies on the host immune response, including targeted small-molecule and antibody approaches that were not previously thought to have an immune component. Here, we review the current understanding of how targeted therapies on tumor cells could have a major impact on the immune response, and how this relates to the therapeutic efficacy of these approaches. In this context, we evaluate different strategies that combine targeted therapies with immunotherapy approaches, and discuss past and ongoing clinical trials. We highlight gaps in knowledge, and argue that significant progress for combined therapies will require a better understanding of the complex interactions between immune cells, the tumor, and the tumor microenvironment (TME) in different cancer settings.",
author = "Xu, {Meng Michelle} and Yang Pu and Yuan Zhang and Fu, {Yang Xin}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.it.2015.12.007",
language = "English (US)",
volume = "37",
pages = "141--153",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies

AU - Xu, Meng Michelle

AU - Pu, Yang

AU - Zhang, Yuan

AU - Fu, Yang Xin

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Accumulating evidence indicates that the efficacy of tumor-targeted therapies relies on the host immune response, including targeted small-molecule and antibody approaches that were not previously thought to have an immune component. Here, we review the current understanding of how targeted therapies on tumor cells could have a major impact on the immune response, and how this relates to the therapeutic efficacy of these approaches. In this context, we evaluate different strategies that combine targeted therapies with immunotherapy approaches, and discuss past and ongoing clinical trials. We highlight gaps in knowledge, and argue that significant progress for combined therapies will require a better understanding of the complex interactions between immune cells, the tumor, and the tumor microenvironment (TME) in different cancer settings.

AB - Accumulating evidence indicates that the efficacy of tumor-targeted therapies relies on the host immune response, including targeted small-molecule and antibody approaches that were not previously thought to have an immune component. Here, we review the current understanding of how targeted therapies on tumor cells could have a major impact on the immune response, and how this relates to the therapeutic efficacy of these approaches. In this context, we evaluate different strategies that combine targeted therapies with immunotherapy approaches, and discuss past and ongoing clinical trials. We highlight gaps in knowledge, and argue that significant progress for combined therapies will require a better understanding of the complex interactions between immune cells, the tumor, and the tumor microenvironment (TME) in different cancer settings.

UR - http://www.scopus.com/inward/record.url?scp=84983196456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983196456&partnerID=8YFLogxK

U2 - 10.1016/j.it.2015.12.007

DO - 10.1016/j.it.2015.12.007

M3 - Review article

C2 - 26778079

AN - SCOPUS:84983196456

VL - 37

SP - 141

EP - 153

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 2

ER -